NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Autoimmune Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > NOD-like Receptor (NLR)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.